ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) ROCE % : 0.00% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

ImmuneOnco Biopharmaceuticals (Shanghai) ROCE % Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) ROCE % Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-47.55

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-	-48.42	-45.84	-58.60	-

ImmuneOnco Biopharmaceuticals (Shanghai) ROCE % Calculation

ImmuneOnco Biopharmaceuticals (Shanghai)'s annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-48.537	/	( ( (113.737 - 7.005)	+	(112.322 - 14.886) )	/ 2 )
	=	-48.537	/	( (106.732	+	97.436)	/ 2 )
	=	-48.537	/	102.084
	=	-47.55 %

ImmuneOnco Biopharmaceuticals (Shanghai)'s ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	0	/	( ( (112.322 - 14.886)	+	(95.179 - 15.338) )	/ 2 )
	=	0	/	( ( 97.436	+	79.841 )	/ 2 )
	=	0	/	88.6385
	=	0.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ImmuneOnco Biopharmaceuticals (Shanghai) ROCE % Related Terms

Thank you for viewing the detailed overview of ImmuneOnco Biopharmaceuticals (Shanghai)'s ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (FRA:R9Z) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

01541:Hong Kong

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

ImmuneOnco Biopharmaceuticals (Shanghai) Headlines

No Headlines